Kurt Conti - Edge Therapeutics Independent Director

Director

Mr. Kurt G. Conti is Independent Director of Edge Therapeutics, Inc. Mr. Conti has served on our board of directors since June 2010 since 2010.
Age 54
Tenure 14 years
Phone800 208-3343
Webwww.edgetherapeutics.com
Conti is Chairman of The Conti Group, where he was the CEO and President since 1995. The Conti Group, originally founded in 1906, is a global developer and builder of capital asset projects. Under his guidance, The Conti Group has completed over $4 billion in projects in 14 countries in the infrastructure, energy, industrial, environmental and security markets. An honors graduate in Civil Engineering from Villanova University, Mr. Conti received the College of Engineering’s Alumni Award for Outstanding Leadership. He is a Harvard University Business School alumnus of the Owner/President Management Program and a recipient of Ernst & Young’s Entrepreneur of the Year award.

Edge Therapeutics Management Efficiency

Edge Therapeutics' management efficiency ratios could be used to measure how well Edge Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 4.17 M in liabilities with Debt to Equity (D/E) ratio of 47.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Edge Therapeutics has a current ratio of 5.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Edge Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Edge Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Edge Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Edge to invest in growth at high rates of return. When we think about Edge Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

James OwensMorgan Stanley
71
Theodore BroomeUniversal
70
Diana CantorUniversal
62
Lennart FreemanUniversal
69
Thomas BartlettEquinix
59
Stephen WolfPhilip Morris International
78
Gary HromadkoEquinix
65
John HughesEquinix
64
Kalpana MorpariaPhilip Morris International
71
Charles FosterUniversal
71
Patrick WillcuttsMorgan Stanley
N/A
Robert PoletPhilip Morris International
65
Thomas GlocerMorgan Stanley
61
Chester CrockerUniversal
72
Simon AugustesenScandinavian Tobacco Group
N/A
Thomas JohnsonUniversal
70
Erskine BowlesMorgan Stanley
70
Mary SchapiroMorgan Stanley
65
Harold BrownPhilip Morris International
90
Nanci CaldwellEquinix
60
Frederik PaulsenPhilip Morris International
70
Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey. Edge Therapeutics operates under Biotechnology classification in USA and is traded on BATS Exchange. Edge Therapeutics (EDGE) is traded on NASDAQ Exchange in USA and employs 14 people.

Management Performance

Edge Therapeutics Leadership Team

Elected by the shareholders, the Edge Therapeutics' board of directors comprises two types of representatives: Edge Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edge. The board's role is to monitor Edge Therapeutics' management team and ensure that shareholders' interests are well served. Edge Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edge Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Macdonald, Chief Scientific Officer, Director
Tuija Soanjarvi, Director
Johan Bolin, Vice President Products
Antonio Perna, Co-founder, Business Coordinator Central Italy; Executive Director
KaiOlaf Dammenhain, Partner, Operations Germany
Joerg Kayser, Partner, Operations Germany
Tom Schmitt, Vice President Sales
Albert Marchio, Chief Accounting and Operations Officer
Gabriel Puente, Operations, Mexico/Managing Director of Techedge Mexico
Anders Hove, Independent Director
Vincenzo Perrone, Independent Director
Andrew CPA, CFO
Enrico Negroni, Chairman of the Board
Sabina Catalano, IR Contact Officer
Domenico Restuccia, Founder, CEO, Director
Giuseppe Vargas, Independent Director
Kelly McGurk, Director of Marketing and Communications
Bradford Middlekauff, Senior Vice President General Counsel, Secretary
Goran Appelquist, CTO
Andrew Saik, CFO
Gunilla Ohman, Investor Relations Manager
Florideo Fabrizio, Co-founder, Research & Development
Brian Leuthner, Co-Founder, CEO and President and Director
Erika Giannetti, Partner, Finance/CFO; Executive Director
Gregory Gin, IR Contact Officer
Jonas Hasselberg, Director
Rosemary Crane, Director
James Loughlin, Independent Director
Massimo Compagnoni, Partner, People
Richard Berg, General Counsel
Jose Rodriguez, Co-founder, Managing Partner Iberia & LATAM, Executive Director
Arnd Benninghoff, Director
Roberto Candido, Partner, Industrial & Services Sector Director
Isaac Blech, Independent Vice Chairman of the Board
Herbert DO, Chief Medical Officer
Fermin Carbajales, Partner, Operations Colombia
Daniel Brennan, COO
Pietro Migliavacca, Co-founder, Operations Italy
Eva Garcia, Partner, Sales Spain
Loch Macdonald, Chief Scientific Officer, Director
Andrew Einhorn, CFO
Herbert Faleck, Chief Medical Officer
Sergio Cipolla, Partner, Operations North America/Managing Director of North America
Jose Soares, Operations, Portugal/Managing Director of Techedge Portugal
Kurt Conti, Independent Director
James Healy, Independent Director
Annachiara Svelto, Independent Director
Liam Ratcliffe, Independent Director
Albert II, Chief Accounting and Operations Officer
Karl Thedeen, CEO, Managing Director
Sigrun Hjelmquist, Independent Director
Beatriz Reyero, Independent Director
Sol Barer, Chairman of the Board
Kent Sander, Independent Director
Giorgio Racca, Partner, Business Development; Executive Director
Michael Ruffolo, Independent Chairman of the Board
Andrea Lavazzi, Partner, Energy & Utilities Sector
Alyssa Wyant, Senior Vice President Regulatory Affairs
BengtArne Molin, Vice President - Research & Development
Jose Navarro, Partner, Operations LATAM; Executive Director
Robert Spiegel, Independent Director
Richard Brandon, Chief Marketing Officer
Magnus Larsson, Vice President - Operations

Edge Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edge Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Edge Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edge Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edge Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Schlumberger could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Schlumberger when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Schlumberger - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Schlumberger NV to buy it.
The correlation of Schlumberger is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Schlumberger moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Schlumberger NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Schlumberger can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Edge Therapeutics information on this page should be used as a complementary analysis to other Edge Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Other Consideration for investing in Edge Stock

If you are still planning to invest in Edge Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Edge Therapeutics' history and understand the potential risks before investing.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes